SCHEMBL20928673

SCHEMBL20928673

CC(C)(C)OC(=O)c1c(S)cccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
ALOX15 P16050 2/20 0.40
GRM6 O15303 1/20 0.40
SLC7A5 Q01650 1/20 0.39
ALDH1A1 P00352 5/20 0.36
HSD17B10 Q99714 6/20 0.36
KDM4E B2RXH2 6/20 0.36
HPGD P15428 5/20 0.36
MAPK1 P28482 1/20 0.35
TSHR P16473 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
ESR1 P03372 1/20 0.34
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
HMGB1 P09429 1/20 0.34
GGT1 P19440 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
BLM P54132 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20928896 0.90 GRM6 (0.38) MAPTHDAC8GRM6SLC7A5ALDH1A1
SCHEMBL20928976 0.87 MAPT (0.43) MAPTHDAC8ALOX15GRM6SLC7A5
SCHEMBL6577861 0.85 ALOX15 (0.43) ALOX15GRM6SLC7A5ALDH1A1HSD17B10
SCHEMBL31330407 0.81 ALOX15 (0.43) ALOX15GRM6SLC7A5ALDH1A1HSD17B10
SCHEMBL20928963 0.81 MAPT (0.52) MAPTHDAC8ALOX15ALDH1A1HSD17B10
SCHEMBL976497 0.81 MMP2 (0.47) MAPTALOX15GRM6SLC7A5ALDH1A1
SCHEMBL10547934 0.78 MAPT (0.50) MAPTHDAC8GRM6SLC7A5ALDH1A1
SCHEMBL20928661 0.77 CA12 (0.54) MAPTHDAC8ALDH1A1HSD17B10KDM4E
SCHEMBL5841080 0.77 SLC7A5 (0.42) MAPTALOX15GRM6SLC7A5ALDH1A1
SCHEMBL15397839 0.77 GRM6 (0.40) MAPTALOX15GRM6SLC7A5HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11022880-B2 Chemically amplified positive-type photosensitive resin composition, photosensitive dry film, method of manufacturing photosensitive dry film, method of manufacturing patterned resist film, method of manufacturing substrate with template, method of manufacturing plated article, and mercapto compound TOKYO OHKA KOGYO CO., LTD. (JP) 2021-06-01 US disclosed
US-20190121233-A1 CHEMICALLY AMPLIFIED POSITIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PATTERNED RESIST FILM, METHOD OF MANUFACTURING SUBSTRATE WITH TEMPLATE, METHOD OF MANUFACTURING PLATED ARTICLE, AND MERCAPTO COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190121233-A1 CHEMICALLY AMPLIFIED POSITIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PATTERNED RESIST FILM, METHOD OF MANUFACTURING SUBSTRATE WITH TEMPLATE, METHOD OF MANUFACTURING PLATED ARTICLE, AND MERCAPTO COMPOUND CUTA, POLR1C, ASIC1 MAPT 1711/4885HDAC8 4748/4885ALOX15 905/4885
US-11022880-B2 Chemically amplified positive-type photosensitive resin composition, photosensitive dry film, method of manufacturing photosensitive dry film, method of manufacturing patterned resist film, method of manufacturing substrate with template, method of manufacturing plated article, and mercapto compound CUTA, POLR1C, ASIC1 MAPT 1711/4885HDAC8 4748/4885ALOX15 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.